Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.67 |
| ▸ | HTR2A | P28223 | 18/20 | 0.67 |
| ▸ | HTR2B | P41595 | 8/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965549 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3957133 | 0.88 | HTR2C (0.71) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3957137 | 0.88 | HTR2C (0.71) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3961408 | 0.88 | HTR2C (0.71) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3962679 | 0.88 | HTR2C (0.71) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL3962471 | 0.84 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL3962476 | 0.84 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL3962479 | 0.84 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3962656 | 0.84 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL3962660 | 0.84 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476687-B2 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.